In This Article:
Nektar Therapeutics (NASDAQ:NKTR) First Quarter 2025 Results
Key Financial Results
-
Revenue: US$10.5m (down 52% from 1Q 2024).
-
Net loss: US$50.9m (loss widened by 38% from 1Q 2024).
-
US$0.24 loss per share (further deteriorated from US$0.19 loss in 1Q 2024).
Our free stock report includes 3 warning signs investors should be aware of before investing in Nektar Therapeutics. Read for free now.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Nektar Therapeutics Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 32%. Earnings per share (EPS) also missed analyst estimates by 44%.
Looking ahead, revenue is expected to decline by 5.1% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 8.3%.
Performance of the American Pharmaceuticals industry.
The company's shares are down 22% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with Nektar Therapeutics (at least 1 which is significant), and understanding these should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.